Entrectinib–A Multitargeted TKI

(6:39)

Entrectinib as Treatment for NTRK-Positive Solid Tumors

(6:51)

Entrectinib–Selective ROS Inhibition

(4:45)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC

(4:27)

Dr. Levy on Entrectinib in Oncogene-Driven NSCLC

(1:34)

Entrectinib in patients with solid tumors and brain metastases

(1:31)

ROS1 Treatment Options: Crizotinib and Entrectinib - 2022 Program: Targeted Therapies Forum

(7:7)

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

(2:3)

Breast Cancer Chess Championship: Trastuzumab vs HER2 Receptor

(2:4)

Lenvatinib para cáncer de tiroides. Aspectos prácticos.

(19:30)

Receptor Tyrosine Kinase

(3:54)

How do ALK-inhibitors work in ALK-positive lung cancer?

(2:50)

Transcription Factors, miRNAs and lncRNAs Regulating EMT and Cancer Metastasis

(14:26)

Nutrition in Pancreatic Cancer

(2:17)

Teclistamab - Guest Lecture

(14:31)

Entrectinib is an investigational therapy designed to target cancers

(3:18)

Herceptin: A Multimodal Approach Targeting HER2 Positive Breast Cancer

(3:56)

The Significance of Results for Entrectinib in ROS1+ NSCLC

(47)

Dr. Drilon on Entrectinib in Patients With Advanced Solid Tumors

(1:28)

Considering Available Data for Entrectinib

(4:16)

Dr. Cohen Discusses Entrectinib in Head and Neck Cancer

(2:8)

Dr. Pishvaian Discusses Results of Entrectinib in Metastatic Pancreas Cancer

(1:4)

Dr. Paz-Ares on Entrectinib in NTRK Fusion-Positive NSCLC

(2:17)

Investigational targetted therapeutic, entrectinib, shows promise against range of cancer types

(7:31)

Clinical Benefit of Entrectinib for Patients With Metastatic Pancreatic Cancer

(1:6)

Evaluating Next Steps for Entrectinib in ROS1-Positive NSCLC

(40)

Entrectinib in NTRK fusion-positive non-small cell lung cancer

(2:53)

Entrectinib’s Value as a TRK Inhibitor

(2:55)

Dr. Pishvaian Discusses the Future of Entrectinib for Pancreatic Cancer

(1:1econd)